First 10 runs free
    Intelligence Feed event · Equity · 2026-10-26

    J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab

    Question

    J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab

    Direct answer

    Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-26
    Published
    2026-10-26
    Revision
    1 · 2026-10-28

    Cite as: Market Ontology, “J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab”, revision 1, evidence through 2026-10-26. https://marketontology.com/market-events/2026-10-26/j-j-reports-77-response-rate-in-phase-1b-2-trial-for-subcutaneous-amivantamab-51eec5

    EQUITY
    J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab
    Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026.
    JNJMRK
    Impact
    70
    OCT 26
    SIG
    88%
    JNJMRK
    J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab
    Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026.
    → Clinical response validation accelerates regulatory progression for amivantamab, supporting oncology revenue growth across Johnson & Johnson's pharmaceutical segment.
    Impact
    Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026.
    Affected
    JNJMRK
    Transmission
    Clinical response validation accelerates regulatory progression for amivantamab, supporting oncology revenue growth across Johnson & Johnson's pharmaceutical segment.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    JNJoncology product commercialization potentialUp1-4wJohnson & Johnson reported a 77% response rate in the OrigAMI-4 trial for amivantamab.
    MRKcombination therapy demand for pembrolizumabUp1-4wThe study utilized pembrolizumab in combination with amivantamab.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    JNJUp266.30 2026-10-26PendingPendingPending
    MRKUpagreed140.61 2026-10-26+0.86%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards